

Supplementary material

Kořwacik S, Bińkowski BJ, Stawiski K, Drożdź J. Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation. Pol Heart J. 2024.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Differences between responders and non-responders.

Parameter	Patients who converted to SR (n=36)	Patients who didn't convert to SR (n=6)	P-value
Age (years), median (IQR)	59 (11.25)	63 (11.75)	0.73
LA (mm), median (IQR)	43 (5)	46 (3.5)	0.03
EF% median (IQR)	60% (0)	59% (3.5)	0.20
Male, n (%)	25 (69.4%)	3 (50.0%)	0.64
Diabetes, n (%)	3 (8.3%)	3 (50.0%)	0.04
Hypertension, n (%)	18 (50.0%)	2 (33.3%)	0.75
AFl history, n (%)	9 (25.0%)	1 (16.7%)	1.00

AFl, atrial flutter; EF, ejection fraction; LA, left atrium

Table S2. Group characteristics for fast and slow responders

Parameter	Fast responders (n=16)	Slow responders (n=20)	<i>P</i> -value
Age (years), median (IQR)	58 (10)	60 (12.3)	0.21
LA (mm), median (IQR)	42 (4.3)	44 (5.0)	0.19
EF%, median (IQR)	60% (0)	60% (0)	0.70
Male, n (%)	9 (56.3%)	16 (80,0%)	0.24
Diabetes, n (%)	3 (18.8%)	0 (0%)	0.16
Hypertension, n (%)	5 (31.3%)	13 (65,0%)	0.09
AFI history	3 (18,8%)	6 (30.0%)	1.00

AFI, atrial flutter; EF, ejection fraction; LA, left atrium